Acceleron Pharma Inc. (XLRN): Price and Financial Metrics

Acceleron Pharma Inc. (XLRN): $173.95

0.20 (+0.12%)

POWR Rating

Component Grades













Add XLRN to Watchlist
Sign Up

Industry: Biotech


of 509

in industry


  • Value is the dimension where XLRN ranks best; there it ranks ahead of 50.87% of US stocks.
  • XLRN's strongest trending metric is Growth; it's been moving down over the last 52 weeks.
  • XLRN's current lowest rank is in the Growth metric (where it is better than 5.01% of US stocks).

XLRN Stock Summary

  • For XLRN, its debt to operating expenses ratio is greater than that reported by merely 10.41% of US equities we're observing.
  • XLRN's price/sales ratio is 104.64; that's higher than the P/S ratio of 96.66% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.08 for Acceleron Pharma Inc; that's greater than it is for merely 7.41% of US stocks.
  • Stocks that are quantitatively similar to XLRN, based on their financial statements, market capitalization, and price volatility, are ACET, BCDA, CAPR, EXEL, and CLSD.
  • XLRN's SEC filings can be seen here. And to visit Acceleron Pharma Inc's official web site, go to

XLRN Valuation Summary

  • XLRN's price/sales ratio is 80.6; this is 610.13% higher than that of the median Healthcare stock.
  • Over the past 97 months, XLRN's EV/EBIT ratio has gone down 51.2.
  • Over the past 97 months, XLRN's price/sales ratio has gone up 69.9.

Below are key valuation metrics over time for XLRN.

Stock Date P/S P/B P/E EV/EBIT
XLRN 2021-08-31 80.6 10.7 -36.5 -35.1
XLRN 2021-08-30 80.0 10.6 -36.2 -34.7
XLRN 2021-08-27 78.0 10.3 -35.3 -33.9
XLRN 2021-08-26 76.6 10.1 -34.6 -33.2
XLRN 2021-08-25 76.5 10.1 -34.6 -33.2
XLRN 2021-08-24 75.4 10.0 -34.1 -32.7

XLRN Growth Metrics

  • Its 2 year net income to common stockholders growth rate is now at -26.06%.
  • Its 4 year price growth rate is now at 248.13%.
  • The 5 year net cashflow from operations growth rate now stands at -157.95%.
XLRN's revenue has moved up $87,990,000 over the prior 49 months.

The table below shows XLRN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 101.126 -193.265 -223.632
2021-03-31 112.938 -151.706 -178.562
2020-12-31 92.523 -130.327 -166.03
2020-09-30 105.995 -108.448 -132.21
2020-06-30 87.642 -142.697 -138.334
2020-03-31 75.556 -114.041 -137.745

XLRN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XLRN has a Quality Grade of D, ranking ahead of 18.73% of graded US stocks.
  • XLRN's asset turnover comes in at 0.113 -- ranking 256th of 681 Pharmaceutical Products stocks.
  • BMY, ACUR, and INSM are the stocks whose asset turnover ratios are most correlated with XLRN.

The table below shows XLRN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.113 1 -0.698
2021-03-31 0.140 1 -0.712
2020-12-31 0.131 1 -0.837
2020-09-30 0.177 1 -0.639
2020-06-30 0.178 1 -0.571
2020-03-31 0.148 1 -0.468

XLRN Stock Price Chart Interactive Chart >

Price chart for XLRN

XLRN Price/Volume Stats

Current price $173.95 52-week high $189.99
Prev. close $173.75 52-week low $99.98
Day low $173.50 Volume 196,800
Day high $174.42 Avg. volume 501,260
50-day MA $149.83 Dividend yield N/A
200-day MA $132.46 Market Cap 10.59B

Acceleron Pharma Inc. (XLRN) Company Bio

Acceleron Pharma XLRN is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company was founded in 2003 and is based in Cambridge, Massachusetts.

XLRN Latest News Stream

Event/Time News Detail
Loading, please wait...

XLRN Latest Social Stream

Loading social stream, please wait...

View Full XLRN Social Stream

Latest XLRN News From Around the Web

Below are the latest news stories about Acceleron Pharma Inc that investors may wish to consider to help them evaluate XLRN as an investment opportunity.

SHAREHOLDER ALERT: WeissLaw LLP Reminds MDP, GWB, XLRN and HFC Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | October 22, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UMPQ, XLRN, ADMS, AZPN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 21, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Umpqua Holdings Corporation (NASDAQ:UMPQ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Columbia Banking System, Inc. Under the terms of the agreement, Umpqua shareholders will receive 0.

Yahoo | October 22, 2021

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith Reminds Investors of Investigations Related to the Following Companies: Acceleron Pharma Inc. (NASDAQ:XLRN), Kraton Corporation (NYSE:KRA), Meredith Corporation (NYSE:MDP)

BALA CYNWYD, PA / ACCESSWIRE / October 21, 2021 / Brodsky & Smith reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions.If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will,

Yahoo | October 21, 2021

Bristol Myers Pledges To Offload Acceleron Shares: Bloomberg

Bristol-Myers Squibb Co (NYSE: BMY) is planning to tender its shares in Acceleron Pharma Inc (NASDAQ: XLRN) after Merck & Co Inc (NYSE: MRK) agreed to buy the biotechnology company for $11.5 billion, Bloomberg reported citing people with knowledge of the matter. Bristol-Myers holds an 11.5% stake in Acceleron. Selling the stake will bring the Merck deal closer to completion. Another Acceleron investor, Avoro Capital, which holds about 7% of Acceleron’s stock, said Merck’s deal “drastically under

Yahoo | October 21, 2021

Investigation Alert: Monteverde & Associates PC Reminds Shareholders Of Ongoing Investigation Regarding The Merger

NEW YORK, NY / ACCESSWIRE / October 21, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Acceleron Pharma Inc. (NASDAQ:XLRN) relating to its proposed acquisition by Merck & Co.

Yahoo | October 21, 2021

Read More 'XLRN' Stories Here

XLRN Price Returns

1-mo 8.83%
3-mo 41.64%
6-mo 37.33%
1-year 59.09%
3-year 259.25%
5-year 515.75%
YTD 35.96%
2020 141.31%
2019 21.75%
2018 2.62%
2017 66.30%
2016 -47.66%

Continue Researching XLRN

Here are a few links from around the web to help you further your research on Acceleron Pharma Inc's stock as an investment opportunity:

Acceleron Pharma Inc (XLRN) Stock Price | Nasdaq
Acceleron Pharma Inc (XLRN) Stock Quote, History and News - Yahoo Finance
Acceleron Pharma Inc (XLRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9085 seconds.